Combination Therapy Holds Promise for Newly Diagnosed Systemic AL Amyloidosis Patients
Updated research regarding the ANDROMEDA study presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, indicated the efficacy of subcutaneous daratumumab (DARA SC) and cyclophosphamide, bortezomib, and dexamethasone (CyBorD) as a combination therapy in newly diagnosed light chain (AL) amyloidosis patients. Daratumumab is a previously approved CD38-directed cytolytic antibody …
Combination Therapy Holds Promise for Newly Diagnosed Systemic AL Amyloidosis Patients Read More »